NASDAQ INMB
 

 

Pipeline

Therapies that Target the INNATE IMMUNE Response

 

DN-TNF PlatformDisease FieldPre-clinicalPhase IPhase II (POC)Pivotal EST. NEXT MILESTONE
XPRO™
Early Alzheimer’s
      P2 Data 2024 
XPRO™
NIH logo
Treatment
Resistant Depression
      P2 Start 1H 2024 
pSar DN-TNF DMD
Cancer
Other
        Future Development and/or Partnership 
NK-Priming PlatformDisease FieldPre-clinicalPhase IPhase II (POC)PivotalEST. NEXT MILESTONE
INKmune™
Myelodysplastic Syndrome
ONCOLOGY
      P1 Data 2023
INKmune™
Metastatic CastrationResistant Prostate Cancer
      P1/2 Start 2H 2023

INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm EST